USC Sexual Abuse And Helping Survivors.
Background: The USC Sexual Abuse Scandal In May 2018, the Los Angeles Times broke a shocking story about USC sexual abuse committed by Dr.…
Read moreThe M Blog
Mass Tort Updates from the Frontlines
Real-time litigation alerts, FDA actions, MDL milestones, and industry analysis.
No pay-to-play coverage. No sponsored posts. Just the active torts MTAA is watching, working on, or running campaigns for — published as the news breaks.
What the M Blog covers
The M Blog is Mass Tort Ad Agency's working log of the plaintiff-side mass tort landscape, written by the people running the campaigns. We post when an FDA action changes a tort's trajectory, when an MDL hits a procedural milestone (Daubert ruling, bellwether result, settlement framework), when a new product safety signal appears in FAERS or peer-reviewed literature, and when a tort we're advertising heats up enough to be worth a public note.
Topics covered regularly: active mass tort campaigns (Dupixent, Paragard IUD, 1,4-Dioxane, EtO sterilization, Discord and Roblox child safety, hair relaxer cancer, talc, Video Game Addiction, social media addiction); MDL operational analysis (claimant inventory dynamics, common benefit fund mechanics, settlement-yield math); plaintiff advertising operations (cost-per-signed-retainer benchmarks, qualification standards, intake throughput); and industry context (firm financing, litigation funder dynamics, bar-disciplinary cases against case-buying operations).
No pay-to-play coverage. No sponsored posts. No affiliate links. If MTAA writes about a tort, it's because the tort matters to plaintiff firms making real decisions about where to deploy capital and intake capacity. New posts ship weekly. The full archive is below; filter by category to narrow in on the area you care about.
Want These Updates Direct?
If you're running mass torts at scale, talk to us about getting on the inside list — we share what we're seeing before it goes public.
Get on the List